改善肝功能和非侵入性的纤维化指标在乙型肝炎病毒相关肝

StephenW

J Gastroenterol Hepatol. 2015 Jun 11. doi: 10.1111/jgh.13020. [Epub ahead of print]
Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment.Shin SK1, Kim JH2, Park H1, Kwon OS1, Lee HJ3, Yeon JE3, Byun KS3, Suh SJ4, Yim HJ4, Kim YS1, Kim JH1.
Author information

• 1Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea.
• 2Department of Internal Medicine, Konkuk University School of Medicine, Seoul, South Korea.
• 3Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.
• 4Department of Internal Medicine, Korea University Ansan Hospital, Ansan, South Korea.
  

AbstractBACKGROUND AND AIM: Entecavir (ETV) induces biochemical and histologic improvement of the liver in patients with chronic hepatitis B. This study aimed to confirm that 2 years of ETV treatment improves liver function and non-invasive fibrosis markers in patients with hepatitis B virus (HBV)-associated cirrhosis.
METHODS: A total 472 naïve patients with HBV-associated cirrhosis was treated with ETV for at least 2 years, between March 2007 and December 2012. Model for end-stage liver disease (MELD) and Child-Pugh (CP) score were used to evaluate the improvement of liver function. Aspartate transaminase to platelet ratio index (APRI), FIB-4 index, and fibrosis index (FI) were used to evaluate the improvement of fibrosis.
RESULTS: The final 370 of 472 patients with HBV-associated cirrhosis were enrolled. Mean age was 51 ± 10 years and 240 patients (64.9%) were men. The distribution of CP class was 71.1% in A, 24.6% in B, and 4.3% in C. Mean MELD and CP score changed over the study period from 8.5 ± 4.6 to 6.2 ± 4.2 (P < 0.001) and from 6.2 ± 1.6 to 5.6 ± 0.9 (P < 0.001), respectively. APRI, FIB-4 index, and FI changed from 3.6 ± 4.5 to 1.5 ± 1.5 (P < 0.001), from 7.0 ± 6.2 to 3.9 ± 2.8 (P < 0.001), and from 3.3 ± 0.9 to 2.5 ± 1.1 (P < 0.001), respectively.
CONCLUSIONS: After 2 years of treatment, entecavir improves liver function and non-invasive fibrosis markers in patients with HBV- associated cirrhosis.
This article is protected by copyright. All rights reserved.


KEYWORDS: entecavir; hepatitis B virus; liver fibrosis; liver function

StephenW

ĴGastroenterol肝脏病。 2015年11月DOI：10.1111 / jgh.13020。 [打印EPUB的提前]
改善肝功能和非侵入性的纤维化指标在乙型肝炎病毒相关肝硬化：2年恩替卡韦治疗。
申SK1，金JH2，公园H1，权OS1，李HJ3，妍JE3，卞KS3，徐SJ4，任某HJ4，金YS1，金JH1。
作者信息

    教研室内科，嘉泉大学吉尔医学中心，仁川，韩国。
    教研室内科，建国大学医学院，首尔，韩国。
    3Department内科，韩国九老大学医院，首尔，韩国。
    4Department内科，高丽大学安山医院，安山，韩国。

抽象
背景与目的：

恩替卡韦（ETV）诱导治疗慢性乙型肝炎的肝脏生化和组织学改善本研究旨在确认2年ETV治疗的患者，乙肝病毒改善肝功能及无创肝纤维化指标（HBV）相关肝硬化。
方法：

共有472初治患者与乙肝相关肝硬化恩替卡韦治疗至少2年，2007年3月至十二月2012型号为终末期肝病（MELD）和Child-Pugh分级（CP）的分数被用来评估改善肝功能。天冬氨酸转氨酶血小板比率指数（APRI），FIB-4指数，和纤维化指数（FI）被用来评估纤维化的改善。
结果：

370 472的最终患者乙肝相关性肝硬化患者。平均年龄为51±10岁和240例（64.9％）为男性。 CP类的分布是71.1％，B中24.6％，而在C.平均MELD 4.3％和CP比分改写在研究期间从8.5±4.6至6.2±4.2（P <0.001）和6.2±1.6到5.6±0.9（P <0.001），分别。 APRI，FIB-4指数，和FI从3.6±4.5变为1.5±1.5（P <0.001），从7.0±6.2到3.9±2.8（P <0.001），并从3.3±0.9到2.5±1.1（P < 0.001），分别。
结论：

治疗2年后的，恩替卡韦改善肝功能，并在患者的HBV-相关肝硬化的非侵入性纤维化指标。

这篇文章是受版权保护的。版权所有。
关键词：

恩替卡韦;乙型肝炎病毒;肝纤维化;肝功能

682256

结论:由乙肝造成的肝硬化病人，经过2年恩替治疗，改善了肝功，也改善了肝脏纤维非侵入性指标。